Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma

Clinical Cancer Research

Volumn 16, Issue 14, 2010, Pages 3769-3778

  Bennani Baiti, Idriss M ^a   Cooper, Aaron ^b   Lawlor, Elizabeth R ^b   Kauer, Maximilian ^a   Ban, Jozef ^a   Aryee, Dave N T ^a   Kovar, Heinrich ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7;

ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; EWING SARCOMA; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE NEOPLASMS; COHORT STUDIES; GENE EXPRESSION PROFILING; HUMANS; PHENOTYPE; PROGNOSIS; RECEPTORS, CXCR; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 77954742433     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0558     Document Type: Article

References (43)

1. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-93.
2. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
3. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
5. Brown RC, Dwyer T, Kasten C, et al. Cohort profile: the International Childhood Cancer Cohort Consortium (I4C). Int J Epidemiol 2007;36: 724-30. (Pubitemid 47394135)
6. Carter A, Landier W, Schad A, et al. Successful coordination and execution of nontherapeutic studies in a cooperative group setting: lessons learned from Children's Oncology Group studies. Cancer Epidemiol Biomarkers Prev 2008;17:1665-73.
7. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer 2005;103: 1457-67. (Pubitemid 40410743)
8. In: Ushigome S, Machinami R, Sorensen PH, editors. Ewing sarcoma/ primitive neuroectodermal tumour (PNET). Lyon: IARC Press; 2002.
9. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008;267:226-44.
10. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107:1761-7.
11. Wu X, Lee VC, Chevalier E, Hwang ST. Chemokine receptors as targets for cancer therapy. Curr Pharm Des 2009;15:742-57.
12. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52.
13. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007;104:15735-40.
14. Ban J, Bennani-Baiti IM, Kauer M, et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 2008;68: 7100-9.
15. van Valen F, Masters J. Ewing's sarcoma family of tumors. In: Human cell culture. pp. 55-85Great Britain: Kluwer Academic Publishers; 1999.
16. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 2009;37: D885-90.
17. Parkinson H, Kapushesky M, Kolesnikov N, et al. ArrayExpress update - from an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids Res 2009;37:D868-72.
18. Kadota K, Nakai Y, Shimizu K. Ranking differentially expressed genes from Affymetrix gene expression data: methods with reproducibility, sensitivity, and specificity. Algorithms Mol Biol 2009;4:7.
19. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 2004;3:Article3.
20. Zilliox MJ, Irizarry RA. A gene expression bar code for microarray data. Nat Methods 2007;4:911-3.
21. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21.
22. Su AI, Cooke MP, Ching KA, et al. Large-scale analysis of the human andmouse transcriptomes. Proc Natl Acad SciUS A 2002;99:4465-70.
23. Kauer M, Ban J, Kofler R, et al. A molecular function map of Ewing's sarcoma. PLoS One 2009;4:e5415.
24. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
25. Kim SY, Volsky DJ. PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 2005;6:144.
26. Whitley E, Ball J. Statistics review 4: sample size calculations. Crit Care 2002;6:335-41. (Pubitemid 34863702)
27. Schaefer KL, Eisenacher M, Braun Y, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008;44:699-709.
28. Scotlandi K, Remondini D, Castellani G, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009;27:2209-16.
29. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol 2005;6:R76.
30. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11:421-9. (Pubitemid 46680428)
31. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 2009;10:126-40.
32. Rodriguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007;110:375-84.
33. Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:334-8.
34. Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006;45:469-75.
35. Ferrari S, Bertoni F, Palmerini E, et al. Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:364-8.
36. Silva TA, Ribeiro FL, Oliveira-Neto HH, et al. Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense. Oncol Rep 2007;18:1107-13.
37. Yang X, Lu P, Fujii C, et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer 2006;118:1869-76.
38. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008; 130:1091-103.
39. Maroni P, Bendinelli P, Matteucci E, Desiderio MA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-κB. Carcinogenesis 2007;28:267-79. (Pubitemid 46321842)
40. Aryee DNT, Niedan S, Kauer M, et al. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances malignant properties of Ewing's sarcoma cells in vitro. Cancer Res 2010;70:4015-23.
41. Chansky HA, Barahmand-Pour F, Mei Q, et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res 2004;22:910-7. (Pubitemid 38756277)
42. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 2009;10:445-57.
43. Paulussen M, Ahrens S, Burdach S, et al, European Intergroup Cooperative Ewing Sarcoma Studies. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Ann Oncol 1998;9:275-81.